星謙發展(00640.HK)擬在新交所凱利板雙重主要上市
格隆匯7月16日丨星謙發展(00640.HK)發佈公告,其已議決進行公司普通股(“股份”)在新加坡證券交易所有限公司(“新交所”)凱利板的潛在雙重主要上市(“潛在雙重上市”),惟須(其中包括)(i)待相關監管機構及新交所批準;(ii)達成完成潛在雙重上市所需的所有條件;及(iii)視乎潛在雙重上市時的現行市場氛圍及狀況,方可作實。倘潛在雙重上市得以實現,公司將在聯交所主板及新交所凱利板雙重上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.